ArticleFrontiers in cellular and infection microbiology2022
Clinical and Microbiological Characteristics of Bacteremic Pneumonia Caused by
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Efficacy of traditional Chinese medicine in treating severe pneumonia: A meta-analysis and systematic review.Medicine · 2026Pooled it
- Pathogenic mechanisms and resistance profiles of microbial pulmonary infections in lung cancer: a systematic review.BMC infectious diseases · 2025Pooled it
- Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- RecCVirulence · 2026Article
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The human lung microbiome progressively diminishes in the distal alveolar regions.NPJ biofilms and microbiomes · 2026Article
- Factors associated with severity inNew microbes and new infections · 2026Article
- Therapeutic effect of eravacycline against carbapenem-resistant hypervirulentAntimicrobial agents and chemotherapy · 2026Article
- An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model ofAntimicrobial agents and chemotherapy · 2026Article
- A comparative analysis of CRISPR systems, virulence factors, and antibiotic resistance genes in carbapenem-sensitive and carbapenem-resistantIranian journal of microbiology · 2026Article
- Phage therapy againstFrontiers in microbiology · 2026Review
- Intestinal mucus acts as a nutrient source and signal forMicrobiome research reports · 2026Article
- Genomic and phenotypic characterization of respiratory pathogens from CF pediatric patients from Dnipro, Ukraine.BMC pulmonary medicine · 2025Article
- Development and diagnostic performance of a sensitive multiplex pneumonia pathogen identification assay for emergency department patients with pneumonia.Microbiology spectrum · 2025Article
- A novel mutation ofMicrobiology spectrum · 2025Article
- Article
- Clinical, antibiotic resistance features, and treatment outcomes of Vietnamese patients with community-acquired sepsis caused byIJID regions · 2025Article
- Article
- Clinical characteristics, risk factors and prognosis ofFrontiers in cellular and infection microbiology · 2025Article
- Pulmonary and extra-pulmonary infections caused by classical and hypervirulentFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.